OBJECTIVE: We sought to evaluate the expression of G protein-coupled receptor 30 (GPR30) and estrogen receptor (ER)beta in uterine carcinosarcoma (CS). STUDY DESIGN: Immunohistochemistry was performed using antibodies to GPR30, ERbeta, ERalpha, and progesterone receptor (PR). The staining intensity and percentage of positive cells were scored for each tissue section. Expression levels were compared using the Wilcoxon rank sum test. Correlation was evaluated by Spearman rho and logistic regression. RESULTS: Compared with normal endometrium, CS had lower ERalpha and PR expression (both P < .01) but higher GPR30 epithelial expression (P = .03). Advanced-stage CS had higher GPR30 (P < .01) and ERbeta (P = .02) epithelial expression compared with early-stage CS. Expression of GPR30 and ERbeta correlated with each other (P < .01), and not with ERalpha or PR. CONCLUSION: In uterine CS, GPR30 and ERbeta are coordinately overexpressed and expression levels increase in advanced-stage disease, supporting the involvement of alternative ERs in disease progression. Copyright 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: We sought to evaluate the expression of G protein-coupled receptor 30 (GPR30) and estrogen receptor (ER)beta in uterine carcinosarcoma (CS). STUDY DESIGN: Immunohistochemistry was performed using antibodies to GPR30, ERbeta, ERalpha, and progesterone receptor (PR). The staining intensity and percentage of positive cells were scored for each tissue section. Expression levels were compared using the Wilcoxon rank sum test. Correlation was evaluated by Spearman rho and logistic regression. RESULTS: Compared with normal endometrium, CS had lower ERalpha and PR expression (both P < .01) but higher GPR30 epithelial expression (P = .03). Advanced-stage CS had higher GPR30 (P < .01) and ERbeta (P = .02) epithelial expression compared with early-stage CS. Expression of GPR30 and ERbeta correlated with each other (P < .01), and not with ERalpha or PR. CONCLUSION: In uterine CS, GPR30 and ERbeta are coordinately overexpressed and expression levels increase in advanced-stage disease, supporting the involvement of alternative ERs in disease progression. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Pamela A Hershberger; Laura P Stabile; Beatriz Kanterewicz; Mary E Rothstein; Chris T Gubish; Stephanie Land; Yongli Shuai; Jill M Siegfried; Mark Nichols Journal: J Steroid Biochem Mol Biol Date: 2009-05-19 Impact factor: 4.292
Authors: S G Silverberg; F J Major; J A Blessing; B Fetter; F B Askin; S Y Liao; A Miller Journal: Int J Gynecol Pathol Date: 1990 Impact factor: 2.762
Authors: Gloria S Huang; Rebecca C Arend; Maomi Li; Marc J Gunter; Lydia G Chiu; Susan Band Horwitz; Gary L Goldberg Journal: Am J Obstet Gynecol Date: 2009-02-06 Impact factor: 8.661
Authors: Harriet O Smith; Hugo Arias-Pulido; Dennis Y Kuo; Tamara Howard; Clifford R Qualls; Sang-Joon Lee; Claire F Verschraegen; Helen J Hathaway; Nancy E Joste; Eric R Prossnitz Journal: Gynecol Oncol Date: 2009-06-06 Impact factor: 5.482
Authors: Jenna Z Marcus; Merieme Klobocista; Rouzan G Karabakhtsian; Eric Prossnitz; Gary L Goldberg; Gloria S Huang Journal: Int J Gynecol Cancer Date: 2018-03 Impact factor: 3.437
Authors: Beth J Plante; Bruce A Lessey; Robert N Taylor; Wei Wang; Milan K Bagchi; Lingwen Yuan; Jessica Scotchie; Marc A Fritz; Steven L Young Journal: Reprod Sci Date: 2012-02-28 Impact factor: 3.060
Authors: Andrei A Tica; Erica C Dun; Oana S Tica; Xin Gao; Jeffrey B Arterburn; G Cristina Brailoiu; Tudor I Oprea; Eugen Brailoiu Journal: Am J Physiol Cell Physiol Date: 2011-08-24 Impact factor: 4.249